Equazen Pro - capsules
Natural health product licensed in Canada
- Other names
- Equazen Pro - caps
- Licence holder
- Soho Floridis UK Ltd.
- NPN or DIN-HM
- 80130812
- Status
- Active licence
- Licence date
- 24 April 2024
- Revision date
- 26 November 2025
- Form
- Capsule, enrobage gélatine
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Huile de poisson Source : Engraulidae - en entier Potency : 58 mg Docosahexaenoic acid | 400 mg | Not calculated |
| Huile de poisson Source : Engraulidae - en entier Potency : 186 mg Eicosapentaenoic acid | Not specified | Not calculated |
| Oenothera biennis Source : Oenothera biennis - Graine Potency : 20 mg gamma-Linolenic acid | 210 mg | Not calculated |
Non-medicinal ingredients
Extrait de feuilles de romarin, Mélange de concentré de tocophérols (type alpha inférieur), Huile de tournesol, Gélatine, Glycérol
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants et Adolescents | minimum: 6 years ; maximum: 19 years | 3 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps support/maintain (healthy) development of brain/(and), eyes/(and) nerves in children up to 12 years of age. Helps support/maintain brain function. Helps support/maintain cognitive health. May help reduce the symptoms associated with attention deficit hyperactivity disorder (ADHD) in school-age children.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80130812
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.